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Genetic deficiencies of a1-antitrypsin (a1AT) in humans are common and result in an increased susceptibility to emphysema (1). Human a1AT is a 394-amino acid glycoprotein that acts as a suicide inhibitor of a wide range of serine proteases.
In humans, the ajAT gene is expressed in a variety of tissues, including macrophages, kidney, small intestine, pancreas, and liver; the latter is the primary site of expression (1, 2). In normal humans, more than 2 g of a1AT is synthesized daily, resulting in a serum concentration of -2 mg/ml.
The primary function of ajAT is to inhibit neutrophil elastase and thus prevent this protease from causing excessive tissue damage (1). The S and Z a1AT alleles are relatively common (-0.03 and 0.02, respectively) and encode proteins that have reduced stability (S) or are poorly secreted (Z), although they exhibit normal antiprotease activity. Individuals with the SZ and ZZ genotypes have significantly reduced concentrations of a1AT (<0.8 mg/ml) and are at risk of developing the degenerative lung disease emphysema, particularly if they smoke.
Since ajAT normally circulates at 2 mg/ml and has a half-life of 6 days, considerable quantities (=4 g per week per patient) would be required for replacement therapy for afflicted individuals (3) , which amounts to 4000-8000 kg annually to treat the ZZ homozygote population of the United States (4) . Such large amounts of protein will be available only if recombinant DNA technology is used for production.
However, although a1AT does not require its carbohydrate side chains for activity, the in vivo half-life of nonglycosylated alAT (expressed in yeast) is 50-fold lower than that of plasma-derived a1AT (4) . Therefore it would seem prudent to produce alAT in a mammalian expression system capable of making the appropriate posttranslational modifications. Unfortunately, large-scale culture of mammalian cells is expensive and technically demanding and thus far has failed to match the yields necessary for high dosage therapeutics, as exemplified by a1AT.
As an alternative to genetically engineered cell lines, Palmiter et al. (5) proposed that valuable proteins could be harvested from transgenic animals. We have argued that the mammary gland is the organ of choice for the expression of recombinant proteins (6, 7) because large amounts of protein can be synthesized by the mammary gland, secreted into milk, and collected easily without detriment to the animal. We have decided to use sheep for this purpose and have recently demonstrated the production of human factor IX and a1AT in the milk of transgenic sheep (8, 9) . In these sheep, and also in transgenic mice carrying the same hybrid genes, the levels of expression of the transgenes were low. The comparisons of the performance of these hybrid genes Fig. 1 ) was elaborated in which the Pvu II site within the 5' untranslated sequences of the ovine BLG clone SS1 (11, 12) was fused to the Taq I site in the 5' untranslated sequences of a1AT. The first a1AT intron was excluded by using DNA sequences from a cDNA clone, p8alppg, which encodes the M1 variant of a1AT (13) , as the source of the first 80 base pairs of a1AT sequences, extending up to the BamHI site in the second exon. The remainder of the alAT "minigene" comprises a Abbreviations: ajAT, a1-antitrypsin; BLG, 3-lactoglobulin; G, generation n; RID, radial immunodiffusion. tTo whom reprint requests should be addressed.
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6.5-kilobase (kb) BamHI fragment from the human a1AT genomic clone pATp7 [also encoding the M1 variant of a1AT (14) ]. The construct was elaborated in the vector pPOLYIII-I (15), enabling excision of the 10.6-kb insert by using Not I sites in the polylinker sequences. Gel-purified insert DNA was microinjected into pronuclear mouse eggs [collected from (C57BL/6 x CBA)F1 mice after mating with F1 stud males] in order to generate transgenic mice (10, 16) . Lines were propogated by mating with F1 mice.
DNA and RNA Analysis. DNA (for Southern blot analysis) prepared from tail biopsies was digested with restriction enzyme(s), subjected to agarose gel electrophoresis, blotted to Hybond N (Amersham) nylon membranes, and probed with 32P-labeled AATB DNA sequences. RNA was prepared from lactating mice 11 days after parturition by standard methods (17, 18) . Aliquots (10 /ig) of total RNA were fractionated on denaturing Mops/formaldehyde (1-1.5%) agarose gels, transferred to Hybond N membranes (Amersham), and probed with a 32P-labeled 243-base-pair Taq I-Pst I fragment derived from the 3' end of p8alppg (13), which allows mouse and human a1AT mRNAs to be distinguished. DNA probes were labeled by using random primers (19) , and hybridizations were carried out as described by Church and Gilbert (20) .
Analysis of Milk. Milk was collected from lactating females 11 days after parturition as described by Simons et al. (10) . Mouse milk was diluted 1:5 in distilled water, and fat was removed after centrifugation. To prepare whey, 1.0 M HCI was added to give a final pH of4.5, to precipitate the caseins, which were then removed by centrifugation.
Diluted milk or whey samples were solubilized by boiling in loading buffer prior to discontinuous SDS/polyacrylamide (8% or 10%) gel electrophoresis (21) and immunoblotting analysis (22 (23) with goat anti-human a1AT antiserum (PRU) and donkey anti-goat IgG (SAPU). Human a1AT, purified from plasma by using a modification of the method described by Laurell et al. (24) , was iodinated by using chloramine T and used as the tracer, and pooled human plasma was employed for calibration. The detection limits of these methods were 40 ,g/ml (RID) and 5 ,g/ml (RIA), respectively, when applied to defatted murine milk samples, and results were validated by using known amounts of human plasma/serum added to control mouse milk. Trypsin Inhibitory Activity. Dilutions of defatted milk or plasma (40 ,l) were incubated at room temperature with (11, 12) Expression of the AATB Transgene. Expression of the transgene was assessed by analyzing RNA and milk from lactating females that were generally either Go animals or the transgenic G1 offspring of Go males. Three patterns of human a1AT RNA expression were observed after Northern blot analysis (Fig. 2) . In some animals and lines, expression was limited to the mammary gland, whereas in others it was confined to the salivary gland. There were two lines where transcripts were seen in both the mammary and the salivary glands (Table 1) . As judged by comparison with human liver RNA and HepG2 RNA, both mammary and salivary transcripts were, as expected, the same size as human liver a1AT mRNA. One line in particular, AATB 35, showed extremely high levels of expression of a1AT mRNA in the mammary gland, comparable to the level observed in human liver.
Production of Human a1AT in Milk. Milk was analyzed by SDS/PAGE and immunoblotting for the presence of human a1AT protein (Fig. 3a) . Human a1AT was present in milk from all the transgenic animals that had detectable levels of human a1AT mRNA in the mammary gland but was not detected in those that did not express the transgene or expressed it only in the salivary gland. The antiserum to human a1AT cross-reacted with an endogenous mouse protein present in milk, probably murine a1AT. (Fig. 4a) . When milk from line AATB 35 mice was compared with human plasma, it was evident that equivalent amounts of plasma and milk a1AT had similar biological activities (Fig. 4b) The finding of mammary gland expression of the AATB construct in seven transgenic individuals and lines confirmed the efficacy of the construct design. However, salivary expression using the BLG promoter was not anticipated. We (29) . Several other groups have also reported salivary gland expression of hybrid genes in which the promoter and 5' flanking sequences were also derived from mammary-specific genes (30) (31) (32) (33) . Thus, it is possible that the downstream BLG sequences contain a salivary gland-specific negative regulatory element or that positive regulatory elements within the a1AT sequences direct expression to this tissue.
Although the electrophoretic mobilities, in SDS/PAGE, of a1AT from transgenic mouse milk or human plasma are similar, the electrophoretic pattern of a1AT proteins observed in transgenic mouse milk appears more complex. This may reflect differences in the posttranslational modifications of the proteins produced in human liver and mouse mammary gland. Alternatively, human a1AT produced in mouse milk may be more susceptible to degradation during secretion or storage.
Within lines of transgenic mice, some variation in expression was observed. In line 15, low-level a1AT expression was detected in only one of the two animals analyzed, and in line 17, in which both G1 and G2 animals were analyzed, an -2-fold variation in a1AT concentration was observed. This may simply reflect a variation in the total protein content of individual milk samples (10) or variation in the level of transgene expression within a line due to nonuniform genetic backgrounds. We have also noted considerable variation in the level of transgene expression within a line of mice carrying the BLG gene (M.M., unpublished observations).
The level of human a1AT in the milk of line 35 mice is very high, as expected from the level of ajAT mRNA observed in the mammary gland. The a1AT is clearly evident on Coomassie blue-stained gels of total milk proteins (Fig. 3b) . Densitometry of stained gels showed that human a1AT comprises 10% of total milk proteins and more than 30o of the whey proteins. These proportions compare favorably with those obtained for expression of a1AT in bacteria (15% of total cell protein) and yeast (3% of total soluble proteins) and particularly so when compared with eukaryotic cell culture expression (<1 tug per 106 cells per 24 hr) (34-37).
The human a1AT present in the milk of transgenic mice from lines 17 and 35 was shown to be biologically active in a trypsin-inhibition assay. When transgenic mouse milk (mouse 35.11) and pooled human plasma were compared, it was evident that equivalent amounts of plasma and recombinant a1AT had similar capacities to inhibit trypsin (Fig. 4b) , indicating that a1AT synthesized in the mammary gland and secreted into milk is as biologically active as that derived from plasma.
In December 1987, the U.S. Food and Drug Administration licensed the use of a1AT in replacement therapy (1). The methods by which a1AT might be delivered to the critical lung locations include intravenous infusions, aerosol sprays, and gene therapy (38, 39) . It seems likely that gene therapy will be very expensive and not readily available to the many individuals suffering from a1AT deficiency. For replacement therapy by means of aerosols or intravenous infusions to be generally available, large quantities of biologically active and correctly glycosylated a1AT will be required.
In this paper we have described the production of transgenic mice expressing high levels of biologically active human a1AT in their milk. The levels of expression in line 35 are of particular interest and, to our knowledge, represent one of the highest levels of expression of a recombinant protein in any mammalian expression system, including transgenic mice and sheep (9, 40, 41 
